Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer

BACKGROUND: The integration of the non-cross-resistant chemotherapeutic agents capecitabine and vinorelbine into an intensified dose-dense sequential anthracycline- and taxane-containing regimen in high-risk early breast cancer (EBC) could improve efficacy, but this combination was not examined in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Volkmar, Thomssen, Christoph, Schmidt, Marcus, Glados, Manfred, Jackisch, Christian, Heilmann, Volker, Hinke, Axel, Lehnert, Antje, Borowicz, Henryk, Möbus, Volker
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928799/
https://www.ncbi.nlm.nih.gov/pubmed/20712886
http://dx.doi.org/10.1186/1471-2407-10-430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2928799/
https://www.ncbi.nlm.nih.gov/pubmed/20712886
http://dx.doi.org/10.1186/1471-2407-10-430

Ejemplares similares